Compare TKNO & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | BNTC |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.7M | 396.3M |
| IPO Year | 2021 | 2020 |
| Metric | TKNO | BNTC |
|---|---|---|
| Price | $9.11 | $9.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $9.00 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 254.4K | 138.5K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $13.53 | N/A |
| Revenue Next Year | $14.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $9.26 |
| 52 Week High | $9.48 | $16.76 |
| Indicator | TKNO | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 71.09 | 29.86 |
| Support Level | $4.87 | N/A |
| Resistance Level | $9.48 | $13.75 |
| Average True Range (ATR) | 0.52 | 0.83 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 86.75 | 21.17 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.